Avadel Pharmaceuticals Challenges Legal Hurdle at Federal Circuit Over Narcolepsy Drug Testing

Avadel Pharmaceuticals has appealed to the Federal Circuit, arguing that a Delaware federal court exceeded its authority by preventing the company from testing its narcolepsy drug intended for treating a rare sleep disorder. Avadel contends that the court’s decision to block the testing was based on an alleged patent infringement concerning a similar drug from a competitor. The company maintains that this legal constraint is unwarranted, impeding the development of a potentially beneficial treatment. For further details, visit the Law360 article.